Table 2.
Antibiotic consumption and duration comparisons between study periods.
| Antibacterial Consumption | |||||
|---|---|---|---|---|---|
| Audit 1 (n = 426) | Audit 2 (n = 424) | ||||
| Antibiotic (in >10% of cases) | Number (No.) of cases | Percentage | No. of cases | Percentage | p-value |
| Piperacillin/tazobactam | 218 | 51.17% | 219 | 51.65% | 0.891 |
| Vancomycin | 174 | 40.85% | 127 | 29.95% | 0.001 |
| Co-amoxiclavulanate | 146 | 34.27% | 124 | 29.25% | 0.122 |
| Metronidazole | 137 | 32.16% | 115 | 27.12% | 0.115 |
| Meropenem | 131 | 30.75% | 115 | 27.12% | 0.257 |
| Gentamicin | 106 | 24.88% | 108 | 25.47% | 0.875 |
| Ciprofloxacin | 75 | 17.61% | 47 | 11.08% | 0.008 |
| Clarithromycin | 62 | 14.55% | 57 | 13.44% | 0.693 |
| Linezolid | 53 | 12.44% | 78 | 18.40% | 0.018 |
| Duration of treatment | |||||
| Audit 1 (n = 426) | Audit 2 (n = 424) | ||||
| Antibiotic (in > 10% of cases) | Median (days) | Interquartile range (IQR) (days) | Median (days) | IQR (days) | p-value |
| Piperacillin/tazobactam | 3.67 | (2–6.67) | 3.33 | (2–6) | 0.249 |
| Vancomycin | 4 | (2.22–7.02) | 2.50 | (1.5–5.13) | 0.001 |
| Co-amoxiclavulanate | 2.33 | (1.33–3) | 1.67 | (1.33–2.67) | 0.071 |
| Metronidazole | 3.33 | (1.96–7.51) | 2.67 | (1.67–4.33) | 0.107 |
| Meropenem | 5 | (2.67–8.03) | 6.04 | (2.83–10.32) | 0.348 |
| Gentamicin | 1 | (1–3) | 1.95 | (1–3) | 0.395 |
| Ciprofloxacin | 3.5 | (2–6.66) | 3.00 | (2–6.42) | 0.670 |
| Clarithromycin | 3.5 | (2.5–5.5) | 3.00 | (2–4.5) | 0.127 |
| Linezolid | 3.5 | (2–6.5) | 3.50 | (2–7.38) | 0.875 |
| Antifungal consumption | |||||
| Audit 1 (n = 426) | Audit 2 (n = 424) | ||||
| Antifungal | No. of cases | Percentage | No. of cases | Percentage | p-value |
| Anidulafungin | 72 | 16.90% | 51 | 12.03% | 0.051 |
| Fluconazole | 42 | 9.86% | 42 | 9.91% | 1 |
| Amphotericin B (Liposomal) | 27 | 6.34% | 16 | 3.77% | 0.117 |
| Caspofungin | 9 | 2.11% | 10 | 2.36% | 0.821 |
| Voriconazole | 7 | 1.64% | 8 | 1.89% | 0.802 |
| Duration of treatment | |||||
| Audit 1 (n = 426) | Audit 2 (n = 424) | ||||
| Antifungal | Median (days) | IQR (days) | Median (days) | IQR (days) | p-value |
| Anidulafungin | 4.00 | (2–9) | 4.00 | (2.27–6) | 0.79 |
| Fluconazole | 3.00 | (2–6.75) | 4.95 | (2.5–6) | 0.25 |
| Amphotericin B (Liposomal) | 5.00 | (2–12.08) | 5.46 | (2.25–9.56) | 0.93 |
| Caspofungin | 3.00 | (1.92–4.17) | 4.00 | (2–5) | 0.84 |
| Voriconazole | 5.92 | (2.75–12.52) | 6.00 | (3.88–9.70) | 0.95 |